Noveris Health Sciences Enhances Global Reach by Joining Biotechnology Innovation Organization

Noveris Integrates into Global Biotechnology Network

On July 17, 2026, Noveris Health Sciences Inc., a biotechnology firm focused on developing and commercializing healthcare technologies, announced its membership in the Biotechnology Innovation Organization. This affiliation connects Noveris with a network comprising biotechnology companies, academic and research institutions, state and regional biotech centers, and related organizations. BIO serves as a pivotal platform linking biotechnology entities, researchers, and capital providers worldwide.

Listed on the Canadian Securities Exchange as NVRS, the Frankfurt Stock Exchange as 0NF0, and the OTC market as MYCOF, Noveris views this membership as a strategic move to strengthen its position within the broader biotechnology sector.

Advantages and Industry Access via BIO Membership

Noveris believes that joining BIO will significantly increase its visibility within the biotechnology and life sciences communities. The membership offers access to BIO’s policy committees, investor and partnering events, industry research, and cost-saving programs, which are vital for fostering collaboration and commercialization in the biotech sector.

The company plans to actively engage in various BIO initiatives, highlighting the BIO International Convention as a key event. This convention is recognized as the largest global gathering of biotechnology professionals. Additional opportunities include member programming, policy committees, and partnering initiatives aimed at relationship-building, knowledge exchange, and strategic growth.

Strategic Commitment to the Global Biotechnology Ecosystem

Jason Birmingham, President and CEO of Noveris, emphasized that joining BIO underscores the company’s dedication to being an active participant in the global biotech industry. The affiliation aligns Noveris with leading biotechnology companies, investors, and policymakers worldwide, enhancing its strategic priorities.

The company anticipates that BIO membership will elevate its profile within healthcare and biotechnology landscapes, facilitating relationship-building and long-term strategic development.

BIO’s Influence and Industry Presence

BIO is recognized as the world’s largest advocacy organization representing biotechnology companies, academic and research institutions, state biotech centers, and related entities. Its members operate across the U.S. and in over 35 countries, engaging in innovative healthcare, agricultural, industrial, and environmental biotechnology research and development.

BIO hosts the BIO International Convention, the largest global biotechnology industry event, along with numerous investor and partnering meetings worldwide, fostering networking and collaboration among members and industry stakeholders.

About Noveris Health Sciences

Noveris Health Sciences Inc. focuses on developing, advancing, and commercializing healthcare technologies that address unmet market needs. The company’s shares trade on multiple exchanges, reflecting its access to diverse capital markets.

More information about Noveris’ operations and strategy is available at www.noveris.health. The announcement does not provide detailed information on the company’s product pipeline or clinical programs beyond its general healthcare technology focus.

Forward-Looking Statements and Risk Factors

The announcement includes forward-looking statements about the anticipated benefits of BIO membership, such as increased visibility, collaboration opportunities, stakeholder engagement, event participation, and support for strategic development and commercialization goals. These statements include terms like "expects," "believes," "will," "anticipates," and similar expressions indicating potential outcomes.

Noveris cautions that such statements are based on current management expectations and are subject to risks and uncertainties, including changes in business, market, economic, or regulatory conditions, and the company’s ability to realize benefits from its BIO membership. Additional risks related to operations are also noted.

Investor Impact and Market Strategy

Noveris’ decision to join BIO reflects its intent to deepen engagement with the global biotechnology community. For investors, this move signals management’s focus on leveraging industry platforms to achieve commercialization and strategic growth objectives. The immediate effect on share price remains unclear.

Membership in BIO may enhance Noveris’ visibility among industry stakeholders, investors, and potential partners. Participation in BIO events, policy committees, and programs is expected to support relationship-building and collaboration, although specific success metrics and timelines were not disclosed.

Global Market Access Through Multi-Exchange Listings

Noveris trades on the Canadian Securities Exchange (NVRS), Frankfurt Stock Exchange (0NF0), and OTC market (MYCOF), facilitating access to investors across North America and Europe. BIO membership may further boost the company’s profile among international biotechnology investors.

The announcement does not include updated financial data, share prices, or recent operational metrics. Investors seeking detailed financial and operational information are advised to consult official regulatory filings and the company’s investor relations resources.